Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC]

602 reported adverse events

Drugs of this class: TEBENTAFUSP

These side effects are most commonly reported by patients taking drugs of the Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] class:

# Side effect Count
0 CYTOKINE RELEASE SYNDROME 118
1 PYREXIA 107
2 DISEASE PROGRESSION 73
3 HYPOTENSION 70
4 RASH 69
5 MALIGNANT NEOPLASM PROGRESSION 61
6 CHILLS 59
7 PRODUCT DOSE OMISSION ISSUE 56
8 PRURITUS 44
9 NAUSEA 40
See all common reactions for Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC]

Drugs of the Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 UVEAL MELANOMA 5 0.0893
1 EXERTIONAL RHABDOMYOLYSIS 3 0.0811
2 METASTATIC OCULAR MELANOMA 2 0.0800
3 EYELASH DISCOLOURATION 4 0.0183
4 CHOROID MELANOMA 2 0.0177
5 GLUCOCORTICOID DEFICIENCY 4 0.0095
6 CYTOKINE RELEASE SYNDROME 118 0.0059
7 TREATMENT DELAYED 8 0.0046
8 METASTASES TO SKIN 3 0.0029
9 SKIN HYPOPIGMENTATION 5 0.0028
See all enriched reactions for Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC]